Examining antimicrobial resistance during the COVID-19 pandemic
What Happened? Antimicrobial Resistance During the SARS-CoV-2 (COVID-19) Pandemic
Methodist Health System · NCT06334731
This study looks at how the COVID-19 pandemic has affected the rates of drug-resistant infections in people by comparing data from before and during the pandemic.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 400 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Methodist Health System (other) |
| Locations | 1 site (Dallas, Texas) |
| Trial ID | NCT06334731 on ClinicalTrials.gov |
What this trial studies
This observational study assesses the incidence and rates of antimicrobial-resistant pathogens before and during the COVID-19 pandemic. It focuses on key pathogens such as extended-spectrum beta-lactamase producing Enterobacteriaceae, carbapenem-resistant bacteria, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococci, and C. difficile infections. The study compares data from the pandemic period (March 2020 - February 2025) to the pre-pandemic period (March 2018 - February 2020) to understand the impact of the pandemic on resistance rates.
Who should consider this trial
Good fit: Ideal candidates include patients over 18 years old who were admitted to specific Methodist Health System medical centers during the study period.
Not a fit: Patients who were not admitted to an inpatient or observation status or those who only had outpatient visits may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide critical insights into the trends of antimicrobial resistance, potentially guiding treatment strategies and public health policies.
How similar studies have performed: While the study addresses a known issue of antimicrobial resistance, the specific focus on the impact of the COVID-19 pandemic on these rates is novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * • Patients admitted to Methodist Richardson, Methodist Mansfield, Methodist Charlton, or Methodist Dallas Medical Centers between March 2018 and August 2021. * \>18 years old Exclusion Criteria: * • Outpatient visit * Not admitted to an inpatient or observation status
Where this trial is running
Dallas, Texas
- Methodist Dallas Medical Center — Dallas, Texas, United States (RECRUITING)
Study contacts
- Principal investigator: Mathew Crotty, PharmD — The Methodist Hospital Research Institute
- Study coordinator: Crystee Cooper, DHEd
- Email: clinicalresearch@mhd.com
- Phone: 214-947-1280
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: COVID-19